Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : A    crawled time : 18:03    save search
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $132.73 0.22% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.21% H: 0.17% C: 0.12%
approval fda fda approval nivolumab
Gainers vs Losers
67% 33%

Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K twitter stocktwits trandingview |
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K twitter stocktwits trandingview |

CXM 4 | $11.34 -0.44% 4.27% 1.7M twitter stocktwits trandingview |
Information
PVL 4 | $1.47 -0.68% 4.08% 77K twitter stocktwits trandingview |
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K twitter stocktwits trandingview |
Finance
BSBR | $5.25 2.54% 0.38% 430K twitter stocktwits trandingview |
Finance
DV | News | $29.43 -2.36% 0.24% 1.9M twitter stocktwits trandingview |
Information
JOE 4 | $54.88 1.22% 0.22% 210K twitter stocktwits trandingview |
Finance
JEF 4 | $42.17 1.57% 0.07% 1.8M twitter stocktwits trandingview |
Finance
MUSA 4 | $417.23 1.06% 0.01% 170K twitter stocktwits trandingview |
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.